Innovating Works

EVCYT

Desconocido
LIFESAVER: Living Impact on Fetal Evolution Shelter Analyze Validate Empower Regulations EVERCYTE GMBH participó en un H2020: H2020-LC-GD-2020 In Europe about 75% of all neonatal deaths and 60% of all infant deaths occur in infants born preterm, and worldwide 450 neonatal deaths occ...
2021-09-28 - 2025-10-31 | Financiado
in3: An integrated interdisciplinary approach to animal free chemical and nanomaterial safety assessment EVERCYTE GMBH participó en un H2020: H2020-MSCA-ITN-2016 All chemicals whether they are drugs, cosmetics, agrochemicals or others need to be tested for their safety to man and the environment. The...
2016-08-31 - 2021-06-30 | Financiado
eCHO Systems: Enhancing CHO by Mammalian Systems Biotechnology eCHO systems EVERCYTE GMBH participó en un H2020: H2020-MSCA-ITN-2014 Chinese hamster (CHO) ovary cells are the production host for a +50 billion €/yr biopharmaceuticals market. Current CHO production platforms...
2014-12-05 - 2018-12-31 | Financiado
FRAILOMIC: Utility of omic based biomarkers in characterizing older individuals at risk for frailty its progre... EVERCYTE GMBH participó en un FP7: The forecasted increase in the number of older people for this century will be accompanied by an increase of those with disabilities. Disabi...
Financiado
NANOII: Nanoscopically guided induction and expansion of regulatory hematopoietic cells to treat autoimmune... EVERCYTE GMBH participó en un FP7: We propose a multidisciplinary program, focusing on the development of novel approaches for directing the differentiation, proliferation and...
Financiado
SYBIL: Systems biology for the functional validation of genetic determinants of skeletal diseases EVERCYTE GMBH participó en un FP7: "The aim of SYBIL is to carry out extensive functional validation of the genetic determinants of rare and common skeletal diseases and the a...
Financiado
NANOCARD: Nanopatterned scaffolds for active myocardial implants EVERCYTE GMBH participó en un FP7: Cell therapy and tissue engineering are emerging as novel therapeutic paradigms for myocardial repair. The rationale behind the cell replace...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.